NeoGenomics, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US64049M2098
USD
12.17
0.1 (0.83%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About NeoGenomics, Inc. stock-summary
stock-summary
NeoGenomics, Inc.
Pharmaceuticals & Biotechnology
NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.
Company Coordinates stock-summary
Company Details
12701 Commonwealth Dr Ste 9 , FORT MYERS FL : 33913-8626
stock-summary
Tel: 1 941 92319491 239 6904239
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 80 Schemes (50.65%)

Foreign Institutions

Held by 114 Foreign Institutions (10.67%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Douglas VanOort
Chairman of the Board, Chief Executive Officer
Mrs. Lynn Tetrault
Lead Independent Director
Mr. Steven Jones
Director
Ms. Rachel Stahler
Director
Mr. Bruce Crowther
Independent Director
Dr. Alison Hannah
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
181 Million
(Quarterly Results - Jun 2025)
Net Profit:
-45 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,024 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.21

stock-summary
Return on Equity

-8.32%

stock-summary
Price to Book

1.20